# Therapeutic Potential of Arimoclomol Nanomicelles: In Vitro Impact on Alzheimer’s and Parkinson’s Pathology and Correlation with In Vivo Inflammatory Response

## TL;DR

This study shows that arimoclomol nanomicelles reduce harmful protein buildup and inflammation in Alzheimer’s and Parkinson’s disease models.

## Contribution

Arimoclomol nanomicelles are shown to reduce both protein aggregation and inflammation in neurodegenerative diseases.

## Key findings

- Arimoclomol nanomicelles significantly reduced β-amyloid and α-synuclein aggregation in vitro.
- The nanomicelles reduced leukocyte and neutrophil counts in an acute inflammation model.
- The treatment targets both neurodegenerative and inflammatory processes simultaneously.

## Abstract

This study investigates the potential of arimoclomol-loaded
nanomicelles
for the treatment of neurodegenerative diseases like Alzheimer’s
and Parkinson’s, as well as their anti-inflammatory properties.
Arimoclomol, a coinducer of heat shock proteins (HSPs), has shown
clinical promise in mitigating protein misfolding, a hallmark of these
diseases. In this work, arimoclomol nanomicelles significantly reduced
the aggregation of β-amyloid (Aβ1–42) and α-synuclein (α-syn), key pathological proteins
in Alzheimer’s and Parkinson’s. Additionally, the nanomicelles
demonstrated potent anti-inflammatory effects, reducing leukocyte
and neutrophil counts in an acute inflammation model. These results
suggest that arimoclomol nanomicelles could enhance clinical outcomes
by targeting both neurodegenerative and inflammatory processes, offering
a promising therapeutic strategy for long-term disease management.